The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View by Xavier, Joao B. & Mitchell, Amir
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2020-03-01 
The Cancer Microbiome: Distinguishing Direct and Indirect Effects 
Requires a Systemic View 
Joao B. Xavier 
Memorial Sloan-Kettering Cancer Center 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cancer Biology Commons, Computational Biology Commons, Environmental Microbiology 
and Microbial Ecology Commons, Immunology and Infectious Disease Commons, Neoplasms Commons, 
and the Systems Biology Commons 
Repository Citation 
Xavier JB, Mitchell A. (2020). The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires 
a Systemic View. Open Access Articles. https://doi.org/10.1016/j.trecan.2020.01.004. Retrieved from 
https://escholarship.umassmed.edu/oapubs/4201 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Opinion
The Cancer Microbiome: Distinguishing Direct
and Indirect Effects Requires a Systemic View
Joao B. Xavier,1,* Vincent B. Young,2 Joseph Skufca,3 Fiona Ginty,4 Traci Testerman,5
Alexander T. Pearson,6 Paul Macklin,7 Amir Mitchell,8 Ilya Shmulevich,9 Lei Xie,10 J. Gregory Caporaso,11
Keith A. Crandall,12 Nicole L. Simone,13 Filipa Godoy-Vitorino,14 Timothy J. Griffin,15 Katrine L. Whiteson,16
Heather H. Gustafson,17 Daniel J. Slade,18 Thomas M. Schmidt,19 Marina R.S. Walther-Antonio,20
Tal Korem,21 Bobbie-Jo M. Webb-Robertson,22 Mark P. Styczynski,23 W. Evan Johnson,24
Christian Jobin,25 Jason M. Ridlon,26 Andrew Y. Koh,27 Michael Yu,28 Libusha Kelly,29 and
Jennifer A. Wargo30
The collection of microbes that live in and on the human body – the human
microbiome – can impact on cancer initiation, progression, and response to ther-
apy, including cancer immunotherapy. The mechanisms by which microbiomes
impact on cancers can yield new diagnostics and treatments, but much remains
unknown. The interactions betweenmicrobes, diet, host factors, drugs, and cell–
cell interactions within the cancer itself likely involve intricate feedbacks, and no
single component can explain all the behavior of the system. Understanding the
role of host-associated microbial communities in cancer systems will require a
multidisciplinary approach combining microbial ecology, immunology, cancer
cell biology, and computational biology – a systems biology approach.
The Roles of Microbiomes in Cancer Are Unclear and Require More Investigation
A statistic often cited says that infectious agents cause 20% of cancers worldwide [1]. That fact
perhaps explains why cancer biology tends to viewmicrobes such as viruses (Box 1) and bacteria
(Box 2) as carcinogens to be eliminated. The microbial communities that make up the human
microbiome (see Glossary) impact on many aspects of host biology: nutrient uptake, drug me-
tabolism, inflammation [2], and even behavior [3]. They most likely also influence cancer progres-
sion and treatment, and in ways that can range from harmful to beneficial. Understanding how
microbiomes impact on cancers – directly and indirectly, harmfully and beneficially – could
bring new opportunities for cancer prevention, treatment, and management [4].
Many knowledge gaps remain: microbiomes are complex ecosystems with spatiotemporal
dynamics that emerge from interactions between microbes and with the cells of their host.
Each cancer is itself an ecosystem in which cancer cells interact with each other and with stromal
cells in intricate, dynamic ways. Common factors such as circulatingmetabolites, systemic immu-
nity, etc. can impact on – and be affected by – the two types of ecosystems simultaneously. The
relevant links between microbiomes and cancers may be impossible to reduce to a single com-
ponent. Exploring the role of microbiomes in cancer will likely require a systems biology approach.
The International CancerMicrobiomeConsortiumimade a frank statement in 2019: 'there is currently
no direct evidence that the human commensal microbiome is a key determinant in the
aetiopathogenesis of cancer' [5]. It will be crucial to distinguish direct microbiome effects on cancer
from indirect effects. Direct effects could occur whenmicrobes contact the cancerous tissue directly
and impact on their behaviors. Indirect effects could occur when microbiomes impact on tumors at
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distant sites, such as for example, when the gut microbiome influences host physiology or systemic
inflammation, which then impacts on cancer progression elsewhere (Figure 1). Although there are
few examples so far of microbiomes that impact on cancers directly, the past decade of microbiome
research has showed us that microbiomes influence host physiology in many ways. It is likely that
some of those indirect effects determine the etiopathogenesis of cancer.
Indirect Effects of Microbiomes on Cancer through Metabolism
One aspect of host physiology where the impact of the gut microbiome is well established is the
systemic balance of circulating levels of nutrients and metabolites [6]. A seminal study in the
microbiome literature showed that, when the gut bacteria of obese mice were transferred into
lean germ-free mice, the recipient mice became obese [2]. Importantly, the recipient mice from
obese donors gained more fat than control recipient mice from lean donors, even though both
groups consumed the same number of calories. The bacteria residing in the gut microbiome cat-
alyze many bioreactions that convert metabolites that reach the intestine – either through the diet
or released by the host. The host can absorb or reabsorb some of those microbially converted
metabolites which then enter the circulation [7], and from circulation the microbial products can
reach distant tissues and impact on cancer progression there. In liver cancer, for example, gut
commensals can metabolize bile acids from primary to secondary structures which can recircu-
late and modulate recruitment of natural killer T cells to cancerous liver cells [8]. Other bacteria in
the gut metabolize estrogen, potentially altering the risk of postmenopausal estrogen receptor-
positive breast cancer, even though the breast is far from the gut [9,10]. In men, microbes can
generate 11-oxyandrogens from host glucocorticoids in the gut and urinary tract, whichmay con-
tribute to prostate cancer [11–13].
Antibiotics can damage the gut microbiome and impact on metabolite levels in the plasma [14],
which can affect host cells that interact with cancers in distant tissues. Two metabolites affected
indirectly by antibiotic use – trimethylamine N-oxide and betaine – impact on peritoneal macro-
phages in mice, changing their phenotype to display markers associated with atherosclerosis
[15]. In that example, the antibiotic treatment impacted on the microbiome, which then affected
the levels of circulatingmetabolites in a way that harmed host health. However, the demonstration
that microbiota manipulations can alter macrophage markers could inspire strategies against
cancer. Macrophages are phenotypically very versatile, and some of their phenotypes can actu-
ally promote tumor growth [16]. Engineering a microbiome that reduces the systemic levels of
metabolites, such as lactate that polarizes tumor-associated macrophages [17,18], could poten-
tially turn off the tumor-promoting phenotypes of those macrophages.
The gut microbiome may also influence the central nervous system, mood, and behavior, and po-
tentially impact on cancer. The link between microbiomes and animal behaviors is a hot topic [19],
but this link is probably ancient: animals have always coexisted with microbes and havemany sym-
biotic relationships with their commensals which affect behavior [3]. The reward system of the
brain, a key circuit in emotional processes, can potentiate an antitumor immune response. In a re-
cent study also in mice, activating the reward systemwith chemogenetics shrank lung tumors [20].
The mechanism involved a cascade of effects: the reward system attenuated noradrenergic input
to a major immunological site, the bone marrow. The myeloid-derived suppressor cells became
less immunosuppressive as a result and caused an antitumor response.
Themicrobiota can indirectly impact on the host reward systems [21] and even the host response
to drugs that affect those systems [22]. Therefore, the microbiome could in principle enhance an-
titumor immunity and decrease cancer progression indirectly by altering the psychological state of
the host. A cancer therapy that works on this principle may seem to be science fiction today, but
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the use of probiotics to reduce pain – either directly or indirectly by potentiating analgesics such
as opioids – is already under study (Figure 2) [23]. The interaction between microbiomes and the
central nervous system could at least be leveraged to control cancer symptoms when cures are
unavailable.
Taking full advantage of the potential of the microbiome against cancer requires a better under-
standing of how commensals function. Fortunately, the microbiome field is rapidly expanding
from taxonomic studies to functional studies (Box 3). Some beneficial functions may be pinned
Box 1. Oncogenic Viruses and the Microbiome
The discovery by Rous in 1911 that a virus caused sarcomas in chickens first linked a microbe to cancer [66]. The virus was present in a filtrate that Rous extracted from
cancerous chicken tissue and caused cancer when injected into healthy chickens. Later, Varmus, Bishop, and colleagues expanded on this discovery to detail a genetic
mechanism [67]. The first finding of a genetic origin of cancer was a viral discovery, and it set off an era of cancer molecular biology.
Viruses have had a key role in our understanding of cancer as a genetic disease, but those viruses which have already been discovered to cause cancer in humans
exemplify how the interface betweenmicrobes and cancer can aid cancer prevention. Vaccines against hepatitis B virus and human papillomavirus (HPV) are remarkably
successful to prevent the cancers that these viruses cause: hepatocellular carcinoma and cervical cancer, respectively [68]. Given the link between viruses and cancer, it
is unfortunate that most microbiome studies have a bias for bacteria, and largely ignore viruses. Surprisingly, other microbial constituents of microbiomes also likely in-
fluence the progression of the virus-caused cancers. This is important because most people infected with oncoviruses will never develop cancer, and the factors that
determine the fate of a viral infection remain unclear. In a study of Puerto Rican women with high-risk HPV infections and high cervical cancer rates, significant bacterial
and fungal profile changes were associated with cervical squamous intraepithelial lesions and HPV infections (Figure I). The changes in the cervicovaginal microbiota,
which resides at an interface between the host and the environment, may thus affect susceptibility to disease [69].
Viral microbiome research has challenges that warrant immediate attention: metagenomics and bioinformatics pipelines such as ViromeScan [70] and virMine [71] can
find known viruses, but discovering new viruses that are not yet listed in databases will require new approaches [72]. New experimental methods may selectively detect
viruses – including RNA viruses – from microbiome samples [73]. Solving such technical challenges could help us to understand better the role of bacteriophages in
microbiome ecology. This is therapeutically important: bacteriophage transfer during FMT and abiotic FMT was associated with a positive outcome in patients with re-
current C. difficile infection [74–76], highlighting the complex interkingdom interactions within the microbiota community.
Decreased diversity and dominance of Lactobacillus
Changes in the cervicovaginal microbiome
Increase of anaerobes
Normal Viral infection Dysplasia Invasive cancer
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Figure I. Cervical Cancer Comes with a Shift in the Composition of the Cervicovaginal Microbiome. The microbiome changes from a Lactobacillus-
dominated community to a community enriched in strict anaerobes such as Sneathia sanguinigens andGardnerella vaginallis. Bacterial vaginosis – a dysbiotic phenotype –
is associated with higher risk of HIV and human papillomavirus (HPV) acquisition and transmission, preterm births, and pelvic inflammatory disease and cancer.
Trends in Cancer
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down to specific microbes, such as when a specific commensal belonging to the Bifidobacterium
genus promotes antitumor immunity in mice [24]. However, other functions, such as metabolic
capabilities, may spread across broad phylogenetic clades. In these cases, several microbes
could be used to provide the same function, assuming conservation of function within clades
[25]. In addition, studying the composition of microbiomes in large populations can reveal new
links between commensal members of the microbiome and cancer incidence (Box 4).
Direct Effects of Microbiomes on Cancer
Most studies of direct effects come, perhaps expectedly, from tumors in tissues naturally colo-
nized by commensals: the gut microbiome on colorectal cancer, the lung microbiome on lung
cancer, the skin microbiome on melanoma, the vaginal microbiome on cervical and endometrial
cancers, etc. However, microbes in unexpected tissues can impact on cancer progression and
response to therapy. Pancreatic cancers can have bacteria accidentally introduced bymedical in-
tervention [26–28], and colorectal cancers can bring along gut bacteria when they metastasize to
other tissues such as the liver [29]. Regardless of whether a tissue is already colonized, the direct
interaction between microbes and cancer cells remains poorly understood.
This area of research would benefit greatly from a system that allowsmodular experiments in vivo,
where each component can be changed independently such that the mechanisms of interaction
between cancer cells and microbes can be untangled. Colorectal cancer is the second largest
cause of cancer death in the USA [30]. The key risk factor is genetic predisposition, but the re-
maining factors – diet, lifestyle, and microbiota composition – account for the majority of cases
[31]. Untangling these risks could benefit from a systems approach. Colorectal cancer already
has animal models such as Il10−/−mice, which could provide amodular experimental system. De-
pending on the genetic background, up to 100% of Il10−/−mice develop colitis; with the addition
of the colon-specific carcinogen azoxymethane, 60–80% of these mice develop colon tumors
[32]. Colorectal cancer is itself a modular disease that progresses in stages [33]. The tissue is di-
rectly colonized by a microbial community and its composition in bacteria, virus, and fungi
changes as the disease proceeds through its stages [34–36]. The combination of a well-
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Box 2. The Duplicitous Role of Microbes in Cancer
The best-known bacterial cause of cancer is Helicobacter pylori, which colonizes 50% of people worldwide [77] and is re-
sponsible for ~90% of gastric cancers [1]. Stomach cancer led the list of deadly cancers for the first half of the 20th century.
Its incidence has decreased inWestern countries, possibly thanks to hygiene and antibiotic use, because some antibiotics
taken to treat other infections killH. pylori unintentionally [78]. However,H. pylori exemplifies a paradox: this bacteriummay
have coevolved with humans because it can be transmitted from person to person and could be considered as a normal
component of the stomachmicrobiome [79].H. pylori colonization may even benefit human health because decolonization
increases the risk of severe gastroesophageal reflux disease and its sequelae, Barrett’s esophagus, and adenocarcinoma
of the esophagus [80]. It may also protect against asthma, multiple sclerosis, and IBD [81–83], although it is a risk factor for
type 2 diabetes and some other diseases [84,85]. Therefore, the same microbe could both harm (by causing gastric can-
cer and some diseases) and benefit human health (by preventing other diseases and even cancers in other organs).
This duplicity applies to other microbes [86]. Perhaps the difference between harm and benefit lies in the type of inflamma-
tion caused by the microbe. Human immunity is a subtle balance, and a measured immune response is essential for
homeostasis: a weak immune response can fail to protect against infection, but an excessive response can destroy tissues
or cause autoimmune disorders. IBD, a form of chronic gut inflammation, alters the composition of the luminal microbiota
and enriches for Gram-negative bacteria. Patients with IBD have a higher risk of colorectal cancer, which may be due to
bacteria enriched in the luminal microbiota such as pks+ E. coli [32]. However, inflammation caused by microbes can
be leveraged against cancer. Bacillus Calmette–Guérin (BCG) – a vaccine prepared from an attenuated strain ofMycobac-
terium bovis – is one of the most successful biotherapies that can treat bladder cancer [87]. Moreover, microbiomes may
affect cancers beyond the presence or absence of a specific microbe, and the simpler cases where the effect is attributed
to a single organism may be exceptions more than a general rule. Understanding microbiomes in cancer may require
knowledge of networks to distinguish a homeostatic network from a carcinogenic network, to understand whether those
networks are static or plastic, and to devise methods to convert a carcinogenic network back into a homeostatic network.
Trends in Cancer
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establishedmodel and a disease with a pathway may enable cancer microbiome studies that dis-
cern the roles and mechanisms of microbes in distinct disease stages [37].
Western diets havemany nutrients that can increase intestinal tumors [38]. These diets abound in an-
imal protein and fat, and can increase bile acid secretion into the gastrointestinal tract. Gut commen-
sals can conjugate these bile acids before they are reabsorbed into circulation. One species,Bilophila
wadsworthia, converts taurine to acetate and ammonia, and releases hydrogen sulfide which is car-
cinogenic [39]. However, even when specific microbes such as B. wadsworthia contribute to cancer
progression, other microbes may also impact on the process, which means that the mechanisms in-
volved must be approached systematically. Spatial structure may also play a key role. For example,
microbial biofilm organization has been associatedwith the location of development of colorectal can-
cer [40] and was also shown to promote carcinogenesis in preclinical models [41].
The transition from a localized cancer to a disseminated disease – metastasis – is a key turning
point when many cancers evolve from a curable to an incurable stage. A recent study showed
Trends in Cancer
Figure 1. The Human Microbiome May Interact with a Cancer through Intricate Feedback Loops, and
Investigating the Interaction Networks May Require a Systems Biology Approach. The effect of a microbiome
on a cancer may be direct or indirect, and this is an important distinction. Direct interaction could take place between
microbiomes residing in tissues where the cancer emerges, such as the hypothetical roles illustrated here of the skin
microbiome interacting directly with melanoma; indirect interactions could occur between a microbiome and a cancer
residing in a different tissue. For example, the gut microbiome alters circulating metabolites which in turn affect general
host physiology and could have an indirect effect on the progression of skin cancer or its response to therapy. Diet will
also play a role because it affects the circulating levels of metabolites and the microbiome composition.
Trends in Cancer
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that microbes can travel from primary tumor sites to distal sites together with metastatic cells. The
study focused on Fusobacterium nucleatum, one of the most prevalent bacteria in colorectal can-
cers. Patient biopsies suggested that Fusobacterium and other bacteria from the gut microbiome
travel from the primary tumor to distant metastases (Figure 3). Mouse xenografts from primary co-
lorectal adenocarcinomas show that cancer cells can indeed carry viable Fusobacterium and
transport them to metastatic sites. The ability to carry bacteria was maintained after several pas-
sages and was important for malignancy: reducing the bacterial load by treating the mice with an-
tibiotics reduced tumor growth. These results suggested that antimicrobial interventions could
help in treating colorectal cancers associated with Fusobacterium [42].
However, bacteria that interact directly with cancer cells could actually help to treat cancers by
causing localized inflammation [43]. This serves as additional evidence of the duplicitous role of
bacteria (discussed in Box 2). The interaction becomes even more complex when we consider
that bacteria can drive drug resistance: some bacteria can metabolize the chemotherapeutic can-
cer drug gemcitabine (2',2'-difluorodeoxycytidine) into its inactive form, 2',2'-difluorodeoxyuridine.
The inactivation of the cancer drug requires that bacteria express a long isoform of cytidine deam-
inase, an enzyme that is predominantly present in gammaproteobacteria. Experiments in a mouse
model with subcutaneous syngeneic tumors showed that gammaproteobacteria living inside the
tumor can increase tumor resistance to gemcitabine. A combination therapy of gemcitabine and
Trends in Cancer
Figure 2. Microbiome Engineering Could Reduce Pain in Cancer Patients. In a mousemodel, the probiotic Lactobacillus acidophilusNCFM strain decreased pain
relative to controls and potentiated the effect of opioid analgesics [23].
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ciprofloxacin – a broad-spectrum antibiotic that kills gammaproteobacteria – halted resistance to
the cancer drug [26], serving as another example of how antibiotics could be used in cancer
treatment.
The Microbiome and Cancer Immunotherapy
Understanding the intricate feedback between microbes, immunity, and cancer – and their im-
pact on immunotherapy – will likely require multidisciplinary approaches and a systems perspec-
tive. Immunotherapy can treat advanced melanoma, and its successes may apply to other
cancers. Up to 60% of patients with metastatic melanoma can now achieve durable remissions
thanks to the ability to unleash the immune system with checkpoint inhibitors [44]. Three papers
published recently suggest that the gut microbiome of a patient can influence their response to
immunotherapy [45–47]. These studies found differences in the gut microbiota composition of
patients who responded to checkpoint inhibitors and patients who did not respond. Intriguingly,
the three studies did not agree on which specific microbes mattered for the success of immuno-
therapy [48]. In addition to a lack of agreement about which commensal microbes matter the
most, the mechanisms by which the gut microbiome influences immunotherapy remain unclear
[49]. The microbiomes of responders can induce the production of interferon (IFN)-γ and gran-
zyme B by CD4 and CD8 T cells, which would help to recruit antitumor macrophages. Check-
point inhibitors are less successful against models of melanoma in germ-free and antibiotic-
treated mice compared with mice with intact gut microbiota [24]. Some studies even suggest
that specific bacteria enriched in responders, such as Bacteroidetes thetaiotaomicron and
Faecalibacterium prausnitzii [50], may be used in precision probiotic treatments to augment the
efficacy of checkpoint inhibitors.
A recent study showed that short-chain fatty acids (SCFAs) produced by gut bacteria promote
the memory potential of antigen-activated CD8+ T cells [51]. This important finding addresses
the healthy skepticism about the disparity in taxa discovered by different groups. F. prausnitzii,
Box 3. Emerging Technologies to Study the Role of Microbiomes in Cancer
Studying the role of microbiomes in cancer will require distinguishing direct effects from indirect effects because they war-
rant different approaches and even different technologies. Direct effects concern microbes that belong to the 'tumor
microbiome', where they can contact cancer cells directly and affect their behaviors. Spatial concerns and tumor hetero-
geneity play a strong role. These studies may require sophisticated imaging in situwhich leaves spatial structure intact. We
could leveragemultiplexed hybridization techniques that label multiple players at the same time: bacteria, mucus, and even
levels of gene expression in the intestinal cells [88,89]. Promising hybridization protocols include CLASI-FISH, which uses a
combination of bacterial probes to show the spatial organization of the microbes [90], and MERFISH, which reveals gene
expression in single cells [91]. Multiplexed hybridization protocols destroy the sample, which means that the technique
cannot be used to follow the same sample across time. The high-resolution cross-sectional data that these methods
do provide are, however, uniquely suited to study spatial organization: the data can lead to new agent-based computa-
tional models that describe how cancer and microbial cells organize themselves in tumors. Agent-based packages such
as PhysiCell, which combines simulation of diffusional gradients and mechanical processes [92], could be expanded to
include bacterial cells and then applied to study inflammation feedback mechanisms that mediate interactions between
cancer cells and microbiomes. Models should be developed with close collaboration between modelers and experimen-
talists to foster feedback between experiment and simulation.
Indirect effects of microbiomes will require analytical methods to study systemic microbiome function; these methods
should integrate microbial composition and function with other relevant data for systems modeling such as habitat, host
information, other omic data, etc. Some bioinformatics tools are already available to study microbiome function, such as
BugBase [93] and PICRUSt2 [94] which seek to quantify the functional composition of commensal microbes using broad
phenotypic categories such as 'anaerobe', 'glucose utilizing', and 'denitrifier'. Other tools, such as QIIME 2 [95], strive to
provide a platform for microbiome multi-omics, or integration of microbiome data types, such as taxonomic profiles,
metagenomes, and metabolomes, to support simultaneous investigation of which microbes are present, their functional
potential, and their metabolic activities, to move beyond studies of microbiome associations to studies of microbiome
mechanisms. Functional studies are already common in other fields of applied microbiology, such as in the biological treat-
ment of wastewater [96], and could be an important tool to link microbiome composition and function.
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which several groups had identified in patients who responded favorably to checkpoint blockade,
is a key clostridial producer of SCFAs including butyrate. The literature on IBD and gut graft-
versus-host disease suggests that these cluster XIVa and IV clostridia produce SCFAs that
then induce a more tolerant and anti-inflammatory environment by inducing regulatory T cells
and interleukin (IL)-10. It had seemed contradictory that gut microbes such as F. prausnitzii
would be beneficial in the context of cancer immunotherapy, but this recent study showed that
these SCFAs may induce different phenotypes depending on various environmental and host-
specific factors [51]. The conditional mechanism explaining why SCFA-producing clostridia im-
pact on immune checkpoint blockade efficacy echoes the point raised earlier that several gut
microbiota members may have a common functional output (e.g., SCFA, butyrate production),
and the metabolites that they produce are functionally important.
Box 4. The Impact of the Environment on Microbiome Composition and its Role in Cancer Incidence
Microbiome studies in large populations can help us to understand changes in the incidence of cancer and lead to new mechanisms linking microbes and cancer. The
microbiota of industrialized populations differs from populations that retain a preindustrial lifestyle, such as the Hadza people who are hunter-gatherers in Tanzania
[97,98]. Industrialized microbiota are less diverse, and the lower diversity may explain high incidences of autoimmune and inflammatory disorders in parts of the world
where our symbiotic relationship with the microbiota has been most affected [99]. Antibiotics, the amount of fiber in diet [100], food additives [101,102], and even ex-
cessive hygiene [103] can also change themicrobiome composition. All these changes can potentially impact on immune responses, cause autoimmune problems, and
compromise our ability to fight pathogens [99], all of which are risk factors for cancer.
A recent study on the microbiomes of US immigrant populations (Figure I) showed that the gut microbiome of migrants changed when they came to the USA: strains
typical of US populations and metagenomic functions displaced native strains and functions in the guts of migrants immediately after migration [104]. The longer the
migrants stayed in the USA, the more their microbiomes changed. The change was even greater in the next generation and – importantly – correlated with obesity.
The changes inmicrobiome composition inmigrants could be simply due to changes in diet. However, it is unknownwhether the different gut microbes could have come
from other humans, raw fruits or vegetables, animals, or even other environmental sources. The loss of microbial diversity could be due to the selective pressure imposed
by a different diet, but it could also be due to exposure to a microbiome in the US environment whichmight be less diverse than that of the original country. Nevertheless,
the suggestion that immigration impacts on microbiome diversity and correlates with health problems that can lead to cancer, such as obesity, justifies efforts to estab-
lish microbiome banks that could be used for microbiome reconstitution. The nonprofit Microbiota Vaultii has a reservoir of 'lost bugs' to rescue the diversity depleted in
the modern era [105]. Another nonprofit venture, the OpenBiome projectiii, has a large sample bank for FMT motivated by the successes of FMT against Clostridioides
difficile colitis [76,106].
Trends in Cancer
Figure I. Migration to the USA Can Lower the Diversity of the Gut Microbiota. This could explain why the incidence of particular diseases – including obesity
and some cancers – increases in some populations of US immigrants. Studying this intriguing phenomenon could provide new clues to the role of microbiomes in
cancer.
Trends in Cancer
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There are other reasons to investigate the gut microbiome of patients receiving immunotherapy:
the therapy has side effects and can itself impact on the gut microbiome, causing more compli-
cations. Checkpoint inhibition can cause immune-mediated colitis [52]. A prospective study of
patients with metastatic melanoma undergoing ipilimumab treatment identified gut bacteria in
the precolitis microbiota of patients that later developed colitis [53]. The patients had fewer bac-
teria from the Bacteroidetes phylum and also lower expression of genes involved in polyamine
transport and B vitamin biosynthesis. If these biomarkers indeed explain why some patients de-
veloped colitis, then this finding could lead to interventions that ameliorate the microbiota and re-
duce the risk of inflammatory complications from cancer immunotherapy. More broadly, the
prospective study illustrates that immunotherapy can cause gut inflammation that then alters
the composition of the microbiome, causing a feedback loop that can lead to more complica-
tions. Remarkably, in a case report serial fecal microbiota transplantation (FMT) alleviated pro-
grammed cell death protein 1 (PD-1)-induced refractory colitis in patients [54].
Restoring Microbiomes after Therapy
Cancer treatments such as radiation and chemotherapy can damage the microbiome and lead to
complications. Patients with prostate, gynecological, or gastrointestinal cancers, for example,
pelvic tumors, often receive pelvic radiotherapy which can be extremely effective (e.g., 90% effec-
tive for prostate cancer). However, pelvic radiotherapy causes chronic diarrhea for which there is
no effective treatment [55–57]. The composition of the gut microbiome at the time a patient re-
ceives the radiation may be responsible for this complication. Specifically, low levels of bacterial
richness in the lower gut before radiation is linked to a higher risk of diarrhea after radiation
Trends in Cancer
Figure 3. Metastases Can Carry Bacteria from the Microbiome of Primary Tumors to Distal Tissues. A recent study [42] investigated patient biopsies from
colorectal cancer and liver metastases from the same patients. Bacteria found in primary tumors, including Fusobacterium nucleatum, were also found in metastases,
suggesting they had traveled with the metastatic cells. Experiments with mice validated these findings and showed that antibiotic treatment could reduce tumor load.
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treatment [58]. Understanding how microbiome composition at the time of the treatment may in-
fluence post-treatment complications requires more systematic analysis.
Cancer patients receiving bonemarrow transplantations experience drastic changes in their gut mi-
crobiota as a result of the large doses of antibiotics given to prevent or treat infections. Antibiotics
are essential because any infection becomes life-threatening if it occurs before the bone marrow
transplant has had time to engraft and the patient is neutropenic. However, the antibiotics cause
collateral damage to the gut commensals: the microbiota loses diversity and may become domi-
nated by bacteria such as vancomycin-resistant Enterococcus faecium [59], which increases the
risk of bloodstream infections and patient mortality [60]. A recent trial conductedwith transplant pa-
tients showed that autologous fecal microbiota transplantation (auto-FMT) can reconstitute
the microbiota composition in patients after they receive bone marrow transplantation (Figure 4)
[61]. The study concluded that auto-FMT restored microbiota composition for the average patient,
but the success varied significantly from patient to patient. In the best case, a patient recovered
practically 100% of their original microbiota composition but, in the worst case, a patient recovered
only 50%. Why successes varied so widely is not known, but could reflect factors such as the ac-
tual composition of themicrobiota transplanted, the state of themicrobiota before the auto-FMT, or
even personal factors including patient genetics or underlying disease. Understanding the variable
success of FMT is an important direction for future research.
Probiotic therapies also vary markedly depending on the resident microbiota of the host [62], but
also depending on differences in genes expressed by the host. This indicates complex interplay
between microbiota ecology and host factors. Stable colonization of the gut microbiome by a
probiotic strain of Bifidobacterium longum depends on the resident microbiome through unclear
Trends in Cancer
Figure 4. Many Cancer Therapies such as Chemotherapy and Pelvic Irradiation Can Damage Healthy Microbiomes. Transplants of intestinal microbiota
such as autologous fecal microbiota transplant (auto-FMT), where a stool sample is collected, cleared for safety, and stored to then be given as a treatment after
microbiota damage, could be used to safely remediate the microbiome of a patient. Auto-FMT has been applied to cancer patients receiving hematopoietic cell
transplantation. Applications to other cancer patients should proceed with caution because we do not fully understand the link between the gut microbiome and
cancer; auto-FMT raises a concern that restoring the pretreatment microbiome composition could increase the odds of cancer recurrence.
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mechanisms [63]. In addition, it is important to consider that success of auto-FMT can be at least
partially compromised by probiotics [64].
Despite the initial successes of auto-FMT to restore the microbiota of cancer patients receiving he-
matopoietic cell transplantations, the same idea may not work as well for other cancers. If the mi-
crobiota has a crucial role in cancer initiation and progression, performing auto-FMT in those
patients could increase the odds of recurrence. Given the current state of our knowledge, auto-
FMT cannot be deemed a risk-free approach for every cancer without further understanding the
role of themicrobiome in a particular disease.We should try to understand better how themicrobes
residing in the gut interact with each other and with the host to improve the success of probiotics
and FMT, and – especially – future personalized cancer therapies based onmicrobiota cocktails
[65].
Concluding Remarks
The many microbes living in and on the human body impact on many aspects of human physiol-
ogy. It seems logical, then, that human microbiomes can impact on cancer prevention, develop-
ment, treatment, and management, although the specific mechanisms remain unclear. The
departure from physiological homeostasis caused by cancer and by cancer therapies can dam-
age microbiomes, which may then increase the risk of more complications. Cancer, cancer treat-
ment, tumor-associated microbes, and the humanmicrobiomemay all be linked through intricate
feedback networks. Untangling these networks and their plasticity requires a systems biology
approach.
The examples discussed here could be taken as invitations to investigate a scientific frontier that
remains largely unexplored (see Outstanding Questions). The field should benefit from recent ad-
vances in microbiome research, as a field evolving from cross-sectional studies that first sought to
catalogue the human microbiome to longitudinal studies that seek to understand function. The
evolution of the microbiome field brings us closer to understanding the dynamic role of
microbiomes in carcinogenesis and cancer progression. The human microbiome is an integrated
part of a large cancer–host–microbiome system. Although each single component may appear to
be insignificant compared with the magnitude of the disease, recent research already shows that
microbiome manipulations can nudge cancer systems towards desired states.
Without better ways to prevent, detect, and treat cancer at an early stage, the number of new
people diagnosed with cancer will continue to outpace the treatments available – even as new
treatments are discovered. That means many of us may need to learn to live with cancer in our
lifetime. It is likely that the solution for prolonging quality and fulfilling lives, even when a cancer
cure is unavailable, resides in our future ability to leverage the human microbiome to help to pro-
vide sustainable, long-term control of the disease. This could help make incurable cancer a
chronic but manageable disease. Once better understood, the homeostasis between microbes
and cancer systems may ultimately contribute to healthier and longer lives.
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Outstanding Questions
What other members of the human
microbiome beyond bacteria –
archaea, fungi, and viruses (including
bacteriophages) – are important for
cancer?
How can we integrate microbial
composition and function with other
relevant data such as habitat, host
information, and other variables
quantified by omic approaches?
Does the human microbiome play a
role in the link between migration and
cancer incidence?
Why does the success of microbiota
transplants vary from patient to
patient?
Can the ability of gut microbes to
influence the central nervous system
be leveraged to manage pain in
cancer patients or even cancer
development?
Can we engineer microbiomes to turn
immunotherapy nonresponders into
responders?
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